Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line

November 24th 2021

Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.

Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer

November 24th 2021

An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.

CTLA-4 Inhibitor AGEN1181 Shows Early Activity in Heavily Pretreated Advanced Solid Tumors

November 23rd 2021

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

Advances With Systemic Therapy and Surgery Underscore the Need for Multidisciplinary Care in Ovarian Cancer

November 22nd 2021

Utilizing a multidisciplinary approach to care is critical in the field of ovarian cancer with the substantial advancements that have been made with systemic chemotherapeutic regimens, PARP inhibitors, maintenance therapy, and surgical interventions.

Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer

November 18th 2021

Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.

Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826

November 18th 2021

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

Addition of Bevacizumab to Pembrolizumab Improves Responses in Epithelial Ovarian Cancer

November 17th 2021

The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.

Lenvatinib Plus Pembrolizumab Displays Strong Efficacy in Advanced Endometrial Cancer

November 15th 2021

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).

Dr. Vaidya on Advances in the Management of Endometrial Cancer

November 11th 2021

Ami P. Vaidya, MD, discusses advances in the management of endometrial cancer.

KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer

November 10th 2021

Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.

Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer

November 10th 2021

Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.

Checkpoint Blockade Moves Needle in Molecularly Driven Endometrial Cancer Paradigm

November 4th 2021

The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.

Ongoing Clinical Trials in Locally Advanced Cervical Cancer

November 3rd 2021

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.

Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial

November 3rd 2021

Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.

Dr. Brown on the Promise of the ROCSAN Trial in Gynecologic Carcinosarcomas

November 2nd 2021

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

The Future Management of Cervical Cancer: Novel Agents and Clinical Pearls for Community Onclogists

November 1st 2021

Rounding out her discussion on the use of tisotumab vedotin in cervical cancer, Rebecca Arend, MD, MPH, considers other agents being investigated and how that may impact the future treatment landscape.

FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

November 1st 2021

A brief review of the FDA approval and implications of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Interim Results of the InnovaTV 205 Trial in Cervical Cancer

November 1st 2021

Considerations for the interim results of innovaTV 205, which tested tisotumab vedotin alone or in combination with other agents for patients with cervical cancer.

InnovaTV 204 Trial in Cervical Cancer: Study Design and Key Efficacy Results

November 1st 2021

Rebecca Arend, MD, MPH, reviews the study design and results from innovaTV 204, which tested tisotumab vedotin in previously treated, recurrent, or metastatic cervical cancer.

Evolving Therapy in Cervical Cancer: Tisotumab Vedotin’s Mechanism of Action

November 1st 2021

A historical perspective on the management of recurrent or metastatic cervical cancer, followed by expert insight on tisotumab vedotin’s mechanism of action.